Table 3. Univariate and multivariate analysis of prognostic factors for overall survival (n = 27).
| Univariate analysis | Multivariate analysis | ||
|---|---|---|---|
| Variable | P value | P value | HR (95%CI) |
| Gender (male vs. female) | 0.783 | ||
| Age (<60 years vs. ≥60 years) | 0.338 | ||
| BMI (<18.5 kg/m2 vs. ≥18.5 kg/m2) | 0.783 | ||
| ECOG PS (0 – 1 vs.2)b | 0.036 | 0.014 | 4.392 (1.352–14.269) |
| CCI (0 vs. 1 – 2) | 0.897 | ||
| Location of primary tumor (upper vs. middle vs. lower) | 0.222 | ||
| Operation (Two-incision vs. Three-incision)b | 0.192 | 0.855 | |
| Postoperative Stage (I – II vs. III)a | 0.566 | ||
| Adjuvant chemotherapy (yes vs. no) | 0.834 | ||
| Recurrence Time (≥1 year vs. <1 year) | 0.684 | ||
| Recurrence site (AR vs. LR) | 0.509 | ||
| Radiation techniques (3D-CRT vs. IMRT) | 0.209 | ||
| Radiation dose (≥56 Gy vs. <56 Gy) | 0.274 | ||
| Chemotherapy (CF vs. NF) | 0.440 | ||
| Tumor Response (CR/PR vs. SD/PD)b | 0.000 | 0.000 | 0.065 (0.014–0.301) |
Abbreviations: 3D-CRT = three-dimensional conformal radiotherapy; AR = anastomosis with/without lymphadenopathy; BMI = body mass index; CCI = Charlson comorbidity index; CF = cisplatin + 5-Fu; CI = confidence interval; CR = complete remission; ECOG PS = Eastern Cooperative Oncology Group Performance Status Scale; HR = Hazard ratio; IMRT = intensity-modulated radiotherapy; LR = supraclavicular and/or regional lymph node; NF = nedaplatin + 5-Fu; PD = progressive disease; PR = partial remission; SD = stable disease;
aTNM stage was according to the 7th edition of the American Joint Commission on Cancer (AJCC) staging system.
bTumor response, ECOG PS, and operation type were selected for further multivariate analysis as they showed a P value <0.20 in univariate analysis.